Implementing medical safety huddles for Patient's Safety

Phase-Based Progress Estimates
Patient's Safety
Implementing medical safety huddles - Other
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial will test whether short, regular meetings between physicians can improve patient safety.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 19 months

15 months
Process measure - Actions taken to address safety issues
Process measure - Attendance rate
Process measure - Safety issues
19 months
Adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Medical Safety Huddles - Pre-implementation
1 of 2
Medical Safety Huddles - Post-implementation
1 of 2

Active Control

Experimental Treatment

4 Total Participants · 2 Treatment Groups

Primary Treatment: Implementing medical safety huddles · No Placebo Group · N/A

Medical Safety Huddles - Post-implementation
Experimental Group · 1 Intervention: Implementing medical safety huddles · Intervention Types: Other
Medical Safety Huddles - Pre-implementationNoIntervention Group · 1 Intervention: Medical Safety Huddles - Pre-implementation · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 19 months

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,369 Previous Clinical Trials
471,889 Total Patients Enrolled
Sinai Health SystemOTHER
20 Previous Clinical Trials
5,095 Total Patients Enrolled
Sunnybrook Health Sciences CentreOTHER
599 Previous Clinical Trials
1,468,412 Total Patients Enrolled
1 Trials studying Patient's Safety
20 Patients Enrolled for Patient's Safety

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: November 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.